ZERVIATE™ (cetirizine ophthalmic solution) 0.24% is indicated for the treatment of ocular itching associated with allergic conjunctivitis.

2 DOSAGE AND ADMINISTRATION

The recommended dosage of ZERVIATE™ is to instill one drop of ZERVIATE™ in each affected eye twice daily (approximately 8 hours apart). The single-use containers are to be used immediately after opening and can be used to dose both eyes. Discard the single-use container and any remaining contents after administration. The single-use containers should be stored in the original foil pouch until ready to use.

3 DOSAGE FORMS AND STRENGTHS

Cetirizine ophthalmic solution, 0.24% is a clear, colorless aqueous solution containing cetirizine 0.24% (equivalent to cetirizine hydrochloride 0.29%). Each mL of ZERVIATE™ contains an active ingredient [cetirizine hydrochloride RS] (equivalent to cetirizine 0.24%) in water for injection. ZERVIATE™ solution has a pH of approximately 6.5 and osmolality of approximately 300 mOsm/kg.

8 USE IN SPECIFIC POPULATIONS

1. Pregnancy

Risk Summary

Cetirizine should be used in pregnancy only if the potential benefit justifies the potential risk to the fetus. There were no adequate or well-controlled studies of ZERVIATE™ in pregnant women. Cetirizine should be used in pregnancy only if the potential benefit justifies the potential risk to the fetus.

5 WARNINGS AND PRECAUTIONS

5.1 Containment of Tip and Solution

As with any eye drop, care should not be taken to touch the eyelids or surrounding areas with the dropper tip of the bottle or tip of the single-use container in order to avoid injury to the eye and to prevent contaminating the tip and solution. Keep the multi-dose bottle closed when not in use. Discard the single-use container after using in each eye.

5.2 Contact Lens Wear

Patients should be advised not to wear a contact lens if their eye is red.

8.5 Geriatric Use

There are no adequate or well-controlled studies of ZERVIATE™ in geriatric patients.

13 NONCLINICAL TOXICOLOGY

8.1 Pregnancy

There is no adequate information regarding the effects of cetirizine on breastfed infants, or the effects on milk production to inform breastfeeding decisions.

16 HOW SUPPLIED/STORAGE AND HANDLING

ZERVIATE™ is a sterile ophthalmic solution containing cetirizine, which is a histamine-1 (H1) receptor antagonist, for topical administration to the eyes. Cetirizine hydrochloride is a white, crystalline, water-soluble powder with a molecular weight of 461.8 and a molecular formula of C24H20ClN2O2. The chemical structure is presented below.

Chemical Name: (RS)-2-[2-[4-(4-Chlorophenyl)-phenylmethyl] piperazin-1-yl] ethyl acetate, dihydrochloride

Each mL of ZERVIATE™ contains an active ingredient [cetirizine 2.40 mg (equivalent to 2.85 mg of cetirizine hydrochloride)] and the following inactive ingredients: benzalkonium chloride (0.010% preservative); glycine; sodium phosphate, dibasic; edetate disodium; polyethylene glycol 400; polysorbate 80; hydrotocin; hydroxypropylcellulose (to adjust pH); and water for injection. ZERVIATE™ solution has a pH of approximately 7.0 and osmolality of approximately 300 mOsm/kg.
In healthy subjects, bilateral topical ocular dosing of one drop of ZERVIATE™ resulted in a mean cetirizine plasma C_max of 1.7 ng/mL following a single dose and 3.1 ng/mL after twice-daily dosing for one week. The observed mean terminal half-life of cetirizine was 8.6 hours following a single dose and 8.2 hours after twice-daily dosing of ZERVIATE™ for one week.

14 CLINICAL STUDIES

The efficacy of ZERVIATE™ (cetirizine ophthalmic solution) 0.24% was established in three randomized, double-masked, placebo-controlled, conjunctival allergen challenge (CAC) clinical trials in patients with a history of allergic conjunctivitis. Duration and duration of action were evaluated in two of these trials in which patients were randomized to receive ZERVIATE™ or vehicle ophthalmic solutions. Patients were evaluated with an ocular itching severity score ranging from 0 (no itching) to 4 (incapacitating itch) at several time points after CAC administration. Table 1 displays data from the mean ocular itching severity scores after ocular administration of an antihistamine using the CAC model. A one unit difference compared to vehicle is considered a clinically meaningful change in the ocular itching severity score.

Patients treated with ZERVIATE™ demonstrated statistically and clinically significantly less ocular itching compared to vehicle at 15 minutes and 8 hours after treatment.

16 HOW SUPPLIED/STORAGE AND HANDLING

ZERVIATE™ is a sterile, buffered, colorless aqueous solution containing cetirizine 0.24% equivalent to cetirizine hydrochloride (0.29%) supplied in a white low-density polyethylene multi-dose ophthalmic bottle with a low-density polyethylene dropper tip and a white polypropylene cap. ZERVIATE™ is supplied in a 7.5 mL bottle that contains 5 mL and a 10 mL bottle that contains 7.5 mL cetirizine ophthalmic solution, 2.40 mg (equivalent to 2.85 mg cetirizine hydrochloride in one mL solution). ZERVIATE™ is also supplied in 5 low-density polyethylene 0.2 mL single-use containers within a foil pouch.